Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: A review of recent developments

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. A, 1998, Pages

  Neil, Pierre Mac ^a,b  

^a Novartis Pharmaceuticals Canada Inc   (Canada)

^b NONE   (Canada)

Author keywords

Cost effectiveness analysis; HMG CoA reductase inhibitors; Hypercholesterolemia

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HYPERCHOLESTEROLEMIA; MORBIDITY; MORTALITY; RESOURCE MANAGEMENT;

ANTICHOLESTEREMIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; SURVIVAL ANALYSIS;

EID: 7144253813     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Chan B, Coyte P, Heick C. Economic impact of cardiovascular disease in Canada. Can J Cardiol 1996;12:1000-6.
2. Thompson D, Oster G. Cost-effectiveness of drug therapy for hypercholesterolemia: a review of the literature. Pharmacoeconomics 1992;2:34-42.
3. Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-7.
4. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results from the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802.
5. Rivière M, Wang S, Leclerc C, Fitzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Can Med Assoc J 1997;156:991-7.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
7. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994;16:1052-62.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
9. Caro J, Klittich W, McGuire A, et al. The cost-effectiveness of preventing initial coronary events with pravastatin: results of the West of Scotland Coronary Prevention Study economic analysis. Proceedings of the Lipid Sessions, XIth International Symposium on Atherosclerosis. Paris, October 5-9, 1997.
10. Kelley MD. Hypercholesterolemia: the cost of treatment in perspective. South Med J 1990;83:1421-5.
11. Moorman JR, Hlatky MA, Eddy DM, Wagner GS. The yield of the routine admission electrocardiogram. A study in general medical service. Ann Intern Med 1985;103:590-5.
12. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985;6:41-63.
13. Evans RW. Cost-effectiveness analysis of transplantation. Surg Clin North Am 1986;66:603-15.
14. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993;269:3015-23.
15. Hogan T. Health and economic issues in the prevention of coronary artery disease. Am J Cardiol 1995;76:140A-2A.
16. Gonzalez ER. Preventing cardiovascular atherosclerosis: role of HMG-CoA reductase inhibitors. Formulary 1996;31:582-602.
17. Kong SX, Gandhi S, Crawford S, Seeger J. Pharmacoeconomic evaluation of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia. Am J Managed Care 1996;2:1055-72.
18. Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis A. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic. Am J Cardiol 1995;76:62A-4A.